<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">JAMA Netw Open</journal-id><journal-id journal-id-type="iso-abbrev">JAMA Netw Open</journal-id><journal-title-group><journal-title>JAMA Network Open</journal-title></journal-title-group><issn pub-type="epub">2574-3805</issn><publisher><publisher-name>American Medical Association</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40392556</article-id><article-id pub-id-type="pmc">PMC12093184</article-id>
<article-id pub-id-type="doi">10.1001/jamanetworkopen.2025.11619</article-id><article-id pub-id-type="publisher-id">zld250061</article-id><article-categories><subj-group subj-group-type="category" specific-use="electronic"><subject>Research</subject></subj-group><subj-group subj-group-type="heading"><subject>Research Letter</subject></subj-group><subj-group subj-group-type="online-only"><subject>Online Only</subject></subj-group><subj-group subj-group-type="subject-area"><subject>Substance Use and Addiction</subject></subj-group></article-categories><title-group><article-title>Postdischarge Alcohol Cessation and Psychiatric Referrals in Alcoholic Liver Disease</article-title><alt-title alt-title-type="headline">Postdischarge Alcohol Cessation and Psychiatric Care in Alcoholic Liver Disease</alt-title><alt-title alt-title-type="running-head">Postdischarge Alcohol Cessation and Psychiatric Care in Alcoholic Liver Disease</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Chan</surname><given-names>Shu-Yen</given-names></name><degrees>MD</degrees><degrees>MSc</degrees><xref rid="zld250061aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Yeo</surname><given-names>Yee Hui</given-names></name><degrees>MD</degrees><degrees>MSc</degrees><xref rid="zld250061aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="zld250061aff3" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Hyunseok</given-names></name><degrees>MD</degrees><degrees>MPH</degrees><degrees>PhD</degrees><xref rid="zld250061aff3" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Polpichai</surname><given-names>Natchaya</given-names></name><degrees>MD</degrees><xref rid="zld250061aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Tsai</surname><given-names>Yueh-Ting</given-names></name><degrees>MD</degrees><xref rid="zld250061aff4" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Ting</surname><given-names>Peng-Sheng</given-names></name><degrees>MD</degrees><xref rid="zld250061aff5" ref-type="aff">
<sup>5</sup>
</xref><xref rid="zld250061aff6" ref-type="aff">
<sup>6</sup>
</xref></contrib></contrib-group><aff id="zld250061aff1"><label>1</label>Department of Internal Medicine, Weiss Memorial Hospital, Chicago, Illinois</aff><aff id="zld250061aff2"><label>2</label>Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California</aff><aff id="zld250061aff3"><label>3</label>Karsh Division of Gastroenterology and Hepatology, Cedars-Sinai Medical Center, Los Angeles, California</aff><aff id="zld250061aff4"><label>4</label>Department of Emergency Medicine, Chung Shan Medical University Hospital, Taichung, Taiwan</aff><aff id="zld250061aff5"><label>5</label>Division of Gastroenterology and Hepatology, Tulane University School of Medicine, New Orleans, Louisiana</aff><aff id="zld250061aff6"><label>6</label>University Medical Center of New Orleans, New Orleans, Louisiana</aff><author-notes><title>Article Information</title><p><bold>Accepted for Publication:</bold> March 19, 2025.</p><p content-type="published-online"><bold>Published:</bold> May 20, 2025. doi:<uri content-type="doi">10.1001/jamanetworkopen.2025.11619</uri></p><p content-type="open-access-note"><bold>Open Access:</bold> This is an open access article distributed under the terms of the <ext-link xlink:href="https://jamanetwork.com/pages/cc-by-license-permissions" ext-link-type="uri">CC-BY License</ext-link>. &#x000a9; 2025 Chan SY et al. <italic>JAMA Network Open</italic>.</p><corresp id="zld250061cor1"><bold>Corresponding Author:</bold> Peng-Sheng Ting, MD, Division of Gastroenterology and Hepatology, Tulane University School of Medicine, 131 S Robertson St, Ste 800, New Orleans, LA 70112 (<email xlink:href="pting1@tulane.edu">pting1@tulane.edu</email>).</corresp><p content-type="author-contributions"><bold>Author Contributions:</bold> Drs Chan and Ting had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.</p><p><italic>Concept and design:</italic> Chan, Yeo, Kim, Tsai, Ting.</p><p><italic>Acquisition, analysis, or interpretation of data</italic>: All authors.</p><p><italic>Drafting of the manuscript:</italic> Chan, Yeo, Kim, Polpichai, Tsai.</p><p><italic>Critical review of the manuscript for important intellectual content</italic>: Chan, Yeo, Kim, Polpichai, Ting.</p><p><italic>Statistical analysis:</italic> Chan, Yeo, Kim, Tsai.</p><p><italic>Administrative, technical, or material support:</italic> Chan, Polpichai.</p><p><italic>Supervision:</italic> Kim, Ting.</p><p content-type="COI-statement"><bold>Conflict of Interest Disclosures:</bold> None reported.</p><p content-type="data-sharing-statement"><bold>Data Sharing Statement:</bold> See <xref rid="note-ZLD250061-1-s" ref-type="supplementary-material">Supplement 2</xref>.</p></author-notes><pub-date pub-type="epub" iso-8601-date="2025-05-20T10:00"><day>20</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>5</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>20</day><month>5</month><year>2025</year></pub-date><!--PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>.--><volume>8</volume><issue>5</issue><elocation-id>e2511619</elocation-id><history><date date-type="received"><day>7</day><month>1</month><year>2025</year></date><date date-type="accepted"><day>19</day><month>3</month><year>2025</year></date></history><permissions><copyright-statement>Copyright 2025 Chan SY et al. <italic>JAMA Network Open</italic>.</copyright-statement><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the CC-BY License.</license-p></license></permissions><self-uri content-type="pdf-version" xlink:href="jamanetwopen-e2511619.pdf">jamanetwopen-e2511619.pdf</self-uri><self-uri content-type="silverchair" xlink:href="https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2025.11619"/><abstract abstract-type="teaser" specific-use="electronic"><p>This cohort study evaluates nationwide trends of postdischarge alcohol relapse prevention treatment for hospitalized individuals.</p></abstract></article-meta></front><body><sec id="H1-1-ZLD250061"><title>Introduction</title><p>Alcohol-associated liver disease (ALD) is a leading cause of liver-related mortality globally<sup><xref rid="zld250061r1" ref-type="bibr">1</xref></sup> and is associated with high rates of recidivism. Rogal et al<sup><xref rid="zld250061r2" ref-type="bibr">2</xref></sup> demonstrated a significant reduction in hepatic decompensation and all-cause mortality among those who received alcohol use disorder (AUD) treatment. However, there is a lack of data on the temporal trends, prevalence of treatment utilization, and disparities across sociodemographic subpopulations in the US. We aim to evaluate nationwide trends of postdischarge alcohol relapse prevention treatment for hospitalized individuals.</p></sec><sec id="H1-2-ZLD250061"><title>Methods</title><p>This population-level cohort study used longitudinal electronic health records from the TriNetX dataset. It was exempt from review and informed consent per the Common Rule and followed the <ext-link xlink:href="http://www.equator-network.org/reporting-guidelines/strobe/" ext-link-type="uri">STROBE</ext-link> reporting guideline. We included individuals aged 21 years or older hospitalized with ALD, including alcohol-associated hepatitis or cirrhosis, from January 1, 2014, to December 31, 2023, identified through diagnosis codes (eTable in <xref rid="note-ZLD250061-1-s" ref-type="supplementary-material">Supplement 1</xref>). The primary outcome was the incidence of common pharmacotherapy prescriptions for alcohol cessation (baclofen, naltrexone, acamprosate, disulfiram, gabapentin, and topiramate), psychiatric referrals, or outpatient psychiatric encounters within a year after discharge. Incidence trends over 10 years were analyzed using Jointpoint Regression Software. Subgroup analyses based on cirrhosis status and sex were performed. To detect significant shifts, we calculated the annual percentage change (APC) and average annual percentage change (AAPC) with 95% CIs. Advanced analyses of nonparallel AAPC comparisons between groups were conducted using permutation tests and parametric methods. For more details, see the eMethods in <xref rid="note-ZLD250061-1-s" ref-type="supplementary-material">Supplement 1</xref>.</p></sec><sec id="H1-3-ZLD250061"><title>Results</title><p>Among 117 million patients in the database, the number of individuals with ALD-related hospitalization tripled, from 11&#x02009;539 in 2014 to 37&#x02009;548 in 2023. Postdischarge pharmacological cessation prescriptions rates in individuals with ALD-related hospitalization increased from 12.6% in 2014 to 23.9% in 2023, with a greater increase between 2014 and 2016 (APC, 17.3%) than from 2016 to 2023 (APC, 5.1%). In contrast, psychiatric referrals or outpatient follow-ups started at a lower baseline 4.8% in 2014, initially declined (APC, &#x02212;6.1% from 2014 to 2017), and then significantly increased from 2017 onward (APC, 8.7%; 95% CI, 5.1%-12.5%), peaking at 6.5% in 2023. Mortality rates among hospitalized individuals with ALD decreased from 16.8% in 2014 to 13.9% in 2017, increased to 15.6% in 2020, and then declined to 13.3% by 2023 (<xref rid="zld250061f1" ref-type="fig">Figure</xref>).</p><fig position="float" id="zld250061f1" fig-type="figure"><label>Figure. </label><caption><title>Trends in Postdischarge Pharmacological Cessation Prescriptions, Psychiatric Referrals or Outpatient Encounters, and Mortality Among Patients With Alcohol-Associated Liver Disease (ALD), 2014-2023, by Cirrhosis Status and Sex</title></caption><graphic xlink:href="jamanetwopen-e2511619-g001" position="float"/></fig><p>Subgroup analysis revealed that individuals with alcohol-associated cirrhosis had lower rates of both pharmacological and psychiatric interventions and higher mortality vs those without cirrhosis. Pharmacological cessation prescriptions significantly increased in both cirrhosis and noncirrhosis groups over the past decade, but only patients without cirrhosis showed a significant increase in psychiatric follow-ups. Women exhibited higher rates of pharmacological cessation prescriptions and psychiatric follow-ups than men, although men exhibited steeper increases in both interventions. Although both sexes demonstrated significant increases in postdischarge pharmacological prescriptions, there were no significant changes in psychiatric follow-ups or mortality over the 10-year period (<xref rid="zld250061t1" ref-type="table">Table</xref>).</p><table-wrap position="float" id="zld250061t1"><label>Table. </label><caption><title>Trends of Pharmacological Cessation Prescriptions, Psychiatric Referrals or Outpatient Encounters and Mortality in Patients With ALD Stratified by Cirrhosis Status and Sex With APC, AAPC, and Nonparallel Comparisons</title></caption><table frame="hsides" rules="groups"><col width="21.76%" span="1"/><col width="11.3%" span="1"/><col width="13.04%" span="1"/><col width="13.91%" span="1"/><col width="12.17%" span="1"/><col width="14.78%" span="1"/><col width="13.04%" span="1"/><thead><tr><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Patient group</th><th colspan="2" valign="top" align="left" scope="colgroup" rowspan="1">Pharmacological cessation prescriptions</th><th colspan="2" valign="top" align="left" scope="colgroup" rowspan="1">Psychiatric referrals or outpatient encounters</th><th colspan="2" valign="top" align="left" scope="colgroup" rowspan="1">Mortality</th></tr></thead><tbody><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Individuals with ALD</td><td colspan="2" valign="top" align="left" rowspan="1"/><td colspan="2" valign="top" align="left" rowspan="1"/><td colspan="2" valign="top" align="left" rowspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Trend 1, years</td><td colspan="2" valign="top" align="left" rowspan="1">2014 to 2016</td><td colspan="2" valign="top" align="left" rowspan="1">2014 to 2017</td><td colspan="2" valign="top" align="left" rowspan="1">2014 to 2017</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> APC, % (95% CI)</td><td colspan="2" valign="top" align="left" rowspan="1">17.3 (9.0 to 26.2)<xref rid="zld250061t1n1" ref-type="table-fn"><sup>a</sup></xref></td><td colspan="2" valign="top" align="left" rowspan="1">&#x02212;6.1 (&#x02212;15.2 to 3.9)</td><td colspan="2" valign="top" align="left" rowspan="1">&#x02212;5.1 (&#x02212;16.1 to 7.5)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Trend 2, years</td><td colspan="2" valign="top" align="left" rowspan="1">2016 to 2023</td><td colspan="2" valign="top" align="left" rowspan="1">2017 to 2023</td><td colspan="2" valign="top" align="left" rowspan="1">2017 to 2021</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> APC, % (95% CI)</td><td colspan="2" valign="top" align="left" rowspan="1">5.1 (4.0 to 6.1)<xref rid="zld250061t1n1" ref-type="table-fn"><sup>a</sup></xref></td><td colspan="2" valign="top" align="left" rowspan="1">8.7 (5.1 to 12.5)<xref rid="zld250061t1n1" ref-type="table-fn"><sup>a</sup></xref></td><td colspan="2" valign="top" align="left" rowspan="1">3.1 (&#x02212;8.9 to 16.7)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Trend 3, years</td><td colspan="2" valign="top" align="left" rowspan="1">NA</td><td colspan="2" valign="top" align="left" rowspan="1">NA</td><td colspan="2" valign="top" align="left" rowspan="1">2021 to 2023</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> APC, % (95% CI)</td><td colspan="2" valign="top" align="left" rowspan="1">NA</td><td colspan="2" valign="top" align="left" rowspan="1">NA</td><td colspan="2" valign="top" align="left" rowspan="1">&#x02212;7.2 (&#x02212;27.6 to 19.0)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> AAPC 2014-2023, % (95% CI)</td><td colspan="2" valign="top" align="left" rowspan="1">7.7 (6.2 to 9.1)<xref rid="zld250061t1n1" ref-type="table-fn"><sup>a</sup></xref></td><td colspan="2" valign="top" align="left" rowspan="1">3.5 (0.4 to 6.8)<xref rid="zld250061t1n1" ref-type="table-fn"><sup>a</sup></xref></td><td colspan="2" valign="top" align="left" rowspan="1">&#x02212;2.0 (&#x02212;5.9 to 2.0)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> AAPC comparison (pharmacology vs psychiatric)</td><td colspan="6" valign="top" align="left" rowspan="1">4.1 (0.6 to 7.7)<xref rid="zld250061t1n1" ref-type="table-fn"><sup>a</sup></xref></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> AAPC comparison (pharmacology vs mortality)</td><td colspan="6" valign="top" align="left" rowspan="1">9.7 (5.4 to 13.9)<xref rid="zld250061t1n1" ref-type="table-fn"><sup>a</sup></xref></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> AAPC comparison (psychiatric vs mortality)</td><td colspan="6" valign="top" align="left" rowspan="1">5.5 (0.4 to 10.6)<xref rid="zld250061t1n1" ref-type="table-fn"><sup>a</sup></xref></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Individuals with ALD, by cirrhosis status</td><td valign="top" align="left" rowspan="1" colspan="1">Cirrhosis</td><td valign="top" align="left" rowspan="1" colspan="1">Noncirrhosis</td><td valign="top" align="left" rowspan="1" colspan="1">Cirrhosis</td><td valign="top" align="left" rowspan="1" colspan="1">Noncirrhosis</td><td valign="top" align="left" rowspan="1" colspan="1">Cirrhosis</td><td valign="top" align="left" rowspan="1" colspan="1">Noncirrhosis</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Trend 1, years</td><td valign="top" align="left" rowspan="1" colspan="1">2014 to 2016</td><td valign="top" align="left" rowspan="1" colspan="1">2014 to 2016</td><td valign="top" align="left" rowspan="1" colspan="1">2014 to 2017</td><td valign="top" align="left" rowspan="1" colspan="1">2014 to 2018</td><td valign="top" align="left" rowspan="1" colspan="1">2014 to 2018</td><td valign="top" align="left" rowspan="1" colspan="1">2014 to 2023</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> APC, % (95% CI)</td><td valign="top" align="left" rowspan="1" colspan="1">16.2 (8.5 to 24.5)<xref rid="zld250061t1n1" ref-type="table-fn"><sup>a</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">18.2 (7.2 to 30.2)<xref rid="zld250061t1n1" ref-type="table-fn"><sup>a</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;7.2 (&#x02212;16.0 to 2.5)</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;2.9 (&#x02212;6.9 to 1.2)</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;3.0 (&#x02212;10.0 to 4.5)</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;3.3 (&#x02212;6.5 to 0.1)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Trend 2, years</td><td valign="top" align="left" rowspan="1" colspan="1">2016 to 2023</td><td valign="top" align="left" rowspan="1" colspan="1">2016 to 2023</td><td valign="top" align="left" rowspan="1" colspan="1">2017 to 2023</td><td valign="top" align="left" rowspan="1" colspan="1">2018 to 2023</td><td valign="top" align="left" rowspan="1" colspan="1">2018 to 2021</td><td valign="top" align="left" rowspan="1" colspan="1">NA</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> APC, % (95% CI)</td><td valign="top" align="left" rowspan="1" colspan="1">4.9 (3.9 to 5.8)<xref rid="zld250061t1n1" ref-type="table-fn"><sup>a</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">6.0 (4.6 to 7.4)<xref rid="zld250061t1n1" ref-type="table-fn"><sup>a</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">8.3 (4.7 to 12.0)<xref rid="zld250061t1n1" ref-type="table-fn"><sup>a</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">11.5 (8.2 to 14.8)<xref rid="zld250061t1n1" ref-type="table-fn"><sup>a</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">5.7 (&#x02212;16.5 to 33.8)</td><td valign="top" align="left" rowspan="1" colspan="1">NA</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Trend 3, years</td><td valign="top" align="left" rowspan="1" colspan="1">NA</td><td valign="top" align="left" rowspan="1" colspan="1">NA</td><td valign="top" align="left" rowspan="1" colspan="1">NA</td><td valign="top" align="left" rowspan="1" colspan="1">NA</td><td valign="top" align="left" rowspan="1" colspan="1">2021 to 2023</td><td valign="top" align="left" rowspan="1" colspan="1">NA</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> APC, % (95% CI)</td><td valign="top" align="left" rowspan="1" colspan="1">NA</td><td valign="top" align="left" rowspan="1" colspan="1">NA</td><td valign="top" align="left" rowspan="1" colspan="1">NA</td><td valign="top" align="left" rowspan="1" colspan="1">NA</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;8.4 (&#x02212;27.6 to 16.0)</td><td valign="top" align="left" rowspan="1" colspan="1">NA</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> AAPC 2014-2023, % (95% CI)</td><td valign="top" align="left" rowspan="1" colspan="1">7.3 (5.9 to 8.7)<xref rid="zld250061t1n1" ref-type="table-fn"><sup>a</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">8.6 (6.6 to 10.6)<xref rid="zld250061t1n1" ref-type="table-fn"><sup>a</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">2.9 (&#x02212;0.2 to 6.0)</td><td valign="top" align="left" rowspan="1" colspan="1">4.8 (2.9 to 6.8)<xref rid="zld250061t1n1" ref-type="table-fn"><sup>a</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;1.4 (&#x02212;5.8 to 3.2)</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;3.3 (&#x02212;6.5 to 0.1)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> AAPC comparison</td><td colspan="2" valign="top" align="left" rowspan="1">&#x02212;1.3 (&#x02212;3.7 to 1.1)</td><td colspan="2" valign="top" align="left" rowspan="1">&#x02212;2.0 (&#x02212;5.7 to 1.7)</td><td colspan="2" valign="top" align="left" rowspan="1">1.8 (&#x02212;3.5 to 7.1)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Individuals with ALD, by sex</td><td valign="top" align="left" rowspan="1" colspan="1">Female</td><td valign="top" align="left" rowspan="1" colspan="1">Male</td><td valign="top" align="left" rowspan="1" colspan="1">Female</td><td valign="top" align="left" rowspan="1" colspan="1">Male</td><td valign="top" align="left" rowspan="1" colspan="1">Female</td><td valign="top" align="left" rowspan="1" colspan="1">Male</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Trend 1, years</td><td valign="top" align="left" rowspan="1" colspan="1">2014 to 2017</td><td valign="top" align="left" rowspan="1" colspan="1">2014 to 2016</td><td valign="top" align="left" rowspan="1" colspan="1">2014 to 2016</td><td valign="top" align="left" rowspan="1" colspan="1">2014 to 2017</td><td valign="top" align="left" rowspan="1" colspan="1">2014 to 2018</td><td valign="top" align="left" rowspan="1" colspan="1">2014 to 2017</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> APC, % (95% CI)</td><td valign="top" align="left" rowspan="1" colspan="1">12.7 (8.7 to 16.9)<xref rid="zld250061t1n1" ref-type="table-fn"><sup>a</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">17.5 (6.3 to 29.8)<xref rid="zld250061t1n1" ref-type="table-fn"><sup>a</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;10.1 (&#x02212;22.6 to 4.6)</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;6.5 (&#x02212;19.7 to 8.9)</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;4.8 (&#x02212;14.9 to 6.5)</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;4.8 (&#x02212;13.6 to 4.8)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Trend 2, years</td><td valign="top" align="left" rowspan="1" colspan="1">2017 to 2023</td><td valign="top" align="left" rowspan="1" colspan="1">2016 to 2023</td><td valign="top" align="left" rowspan="1" colspan="1">2016 to 2023</td><td valign="top" align="left" rowspan="1" colspan="1">2017 to 2023</td><td valign="top" align="left" rowspan="1" colspan="1">2018 to 2021</td><td valign="top" align="left" rowspan="1" colspan="1">2017 to 2021</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> APC, % (95% CI)</td><td valign="top" align="left" rowspan="1" colspan="1">4.1 (2.8 to 5.4)<xref rid="zld250061t1n1" ref-type="table-fn"><sup>a</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">5.3 (3.9 to 6.7)<xref rid="zld250061t1n1" ref-type="table-fn"><sup>a</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">6.5 (4.4 to 8.7)<xref rid="zld250061t1n1" ref-type="table-fn"><sup>a</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">9.8 (4.3 to 15.6)<xref rid="zld250061t1n1" ref-type="table-fn"><sup>a</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">6.7 (&#x02212;25.2 to 52.1)</td><td valign="top" align="left" rowspan="1" colspan="1">2.5 (&#x02212;6.9 to 12.8)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Trend 3, years</td><td valign="top" align="left" rowspan="1" colspan="1">NA</td><td valign="top" align="left" rowspan="1" colspan="1">NA</td><td valign="top" align="left" rowspan="1" colspan="1">NA</td><td valign="top" align="left" rowspan="1" colspan="1">NA</td><td valign="top" align="left" rowspan="1" colspan="1">2021 to 2023</td><td valign="top" align="left" rowspan="1" colspan="1">2021 to 2023</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> APC, % (95% CI)</td><td valign="top" align="left" rowspan="1" colspan="1">NA</td><td valign="top" align="left" rowspan="1" colspan="1">NA</td><td valign="top" align="left" rowspan="1" colspan="1">NA</td><td valign="top" align="left" rowspan="1" colspan="1">NA</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;8.8 (&#x02212;36.0 to 30.1)</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;6.7 (&#x02212;23.0 to 13.1)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> AAPC 2014-2023, % (95% CI)</td><td valign="top" align="left" rowspan="1" colspan="1">6.9 (5.7 to 8.1)<xref rid="zld250061t1n1" ref-type="table-fn"><sup>a</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">7.9 (5.9 to 9.9)<xref rid="zld250061t1n1" ref-type="table-fn"><sup>a</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">2.6 (&#x02212;0.2 to 5.5)</td><td valign="top" align="left" rowspan="1" colspan="1">4.1 (&#x02212;0.7 to 9.1)</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;2.1 (&#x02212;8.5 to 1.4)</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;2.1 (&#x02212;5.1 to 1.0)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> AAPC comparison</td><td colspan="2" valign="top" align="left" rowspan="1">&#x02212;1.0 (&#x02212;3.3 to 1.3)</td><td colspan="2" valign="top" align="left" rowspan="1">&#x02212;1.5 (&#x02212;7.1 to 4.2)</td><td colspan="2" valign="top" align="left" rowspan="1">0.0 (&#x02212;7.3 to 7.4)</td></tr></tbody></table><table-wrap-foot><p>Abbreviations: AAPC, average annual percentage change; ALD, alcohol-associated liver disease; APC, annual percentage change; NA, not applicable.</p><fn id="zld250061t1n1"><label>
<sup>a</sup>
</label><p>Indicates statistical significance at <italic>P</italic>&#x02009;&#x0003c;&#x02009;.05.</p></fn></table-wrap-foot></table-wrap></sec><sec id="H1-4-ZLD250061"><title>Discussion</title><p>This cohort study found increased population-level trends in postdischarge pharmacological cessation prescriptions and psychiatric referrals among hospitalized individuals with ALD, although the proportions remained low. Over the past decade, pharmacological cessation prescriptions have significantly increased, aligning with a Canadian study showing a 10-fold increase in AUD pharmacotherapy.<sup><xref rid="zld250061r3" ref-type="bibr">3</xref></sup> In our study, psychiatric referrals and outpatient encounters encompassed general psychiatric evaluations, rather than being limited to alcohol-specific treatment referrals, due to limitations of dataset in identifying AUD-directed behavioral treatment. Despite this broad definition, psychiatric follow-ups remained low, accounting for only 6.5% in 2023. Individuals with cirrhosis had lower rates of pharmacotherapy cessation prescriptions and psychiatric referrals, likely due to concerns over impaired liver function and perceived limited medication options.<sup><xref rid="zld250061r4" ref-type="bibr">4</xref></sup> Mortality rates peaked in 2020 and have since declined, possibly because of the COVID-19 pandemic and increased pharmacologic and psychiatric interventions since 2017. Whether mortality rates have reached an inflection point that heralds a sustained decline remains to be seen. Inherent limitations for database studies include potential misclassification bias from diagnosis coding and the inability to determine the specific indications for multiuse medications. As abstinence has been proven to reduce the risk of mortality and decompensation across all stages of ALD,<sup><xref rid="zld250061r5" ref-type="bibr">5</xref></sup> our study provides crucial evidence of underutilization and trends of postdischarge pharmacological and psychiatric interventions, particularly among men and individuals with cirrhosis, highlighting the need for targeted strategies to support long-term alcohol cessation.</p></sec></body><back><ref-list id="REF-ZLD250061"><title>References</title><ref id="zld250061r1"><label>1</label><mixed-citation publication-type="journal"><person-group><string-name><surname>Devarbhavi</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Asrani</surname>
<given-names>SK</given-names></string-name>, <string-name><surname>Arab</surname>
<given-names>JP</given-names></string-name>, <string-name><surname>Nartey</surname>
<given-names>YA</given-names></string-name>, <string-name><surname>Pose</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Kamath</surname>
<given-names>PS</given-names></string-name></person-group>. <article-title>Global burden of liver disease: 2023 update</article-title>. <source>J Hepatol</source>. <year>2023</year>;<volume>79</volume>(<issue>2</issue>):<fpage>516</fpage>-<lpage>537</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jhep.2023.03.017</pub-id><pub-id pub-id-type="pmid">36990226</pub-id>
</mixed-citation></ref><ref id="zld250061r2"><label>2</label><mixed-citation publication-type="journal"><person-group><string-name><surname>Rogal</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Youk</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Zhang</surname>
<given-names>H</given-names></string-name>, <etal/></person-group>. <article-title>Impact of alcohol use disorder treatment on clinical outcomes among patients with cirrhosis</article-title>. <source>Hepatology</source>. <year>2020</year>;<volume>71</volume>(<issue>6</issue>):<fpage>2080</fpage>-<lpage>2092</lpage>. doi:<pub-id pub-id-type="doi">10.1002/hep.31042</pub-id><pub-id pub-id-type="pmid">31758811</pub-id>
</mixed-citation></ref><ref id="zld250061r3"><label>3</label><mixed-citation publication-type="journal"><person-group><string-name><surname>Abbott</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Hyrsak</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Bolton</surname>
<given-names>JM</given-names></string-name>, <etal/></person-group>. <article-title>Trend in prescription medication utilization for opioid use disorder and alcohol use disorder from 2015 to 2021: a population-wide study in a Canadian province</article-title>. <source>J Addict Med</source>. <year>2024</year>;<volume>18</volume>(<issue>6</issue>):<fpage>683</fpage>-<lpage>688</lpage>. doi:<pub-id pub-id-type="doi">10.1097/ADM.0000000000001348</pub-id><pub-id pub-id-type="pmid">39012008</pub-id>
</mixed-citation></ref><ref id="zld250061r4"><label>4</label><mixed-citation publication-type="journal"><person-group><string-name><surname>Jophlin</surname>
<given-names>LL</given-names></string-name>, <string-name><surname>Singal</surname>
<given-names>AK</given-names></string-name>, <string-name><surname>Bataller</surname>
<given-names>R</given-names></string-name>, <etal/></person-group>. <article-title>ACG Clinical Guideline: alcohol-associated liver disease</article-title>. <source>Am J Gastroenterol</source>. <year>2024</year>;<volume>119</volume>(<issue>1</issue>):<fpage>30</fpage>-<lpage>54</lpage>. doi:<pub-id pub-id-type="doi">10.14309/ajg.0000000000002572</pub-id><pub-id pub-id-type="pmid">38174913</pub-id>
</mixed-citation></ref><ref id="zld250061r5"><label>5</label><mixed-citation publication-type="journal"><person-group><string-name><surname>Hofer</surname>
<given-names>BS</given-names></string-name>, <string-name><surname>Simbrunner</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Hartl</surname>
<given-names>L</given-names></string-name>, <etal/></person-group>. <article-title>Alcohol abstinence improves prognosis across all stages of portal hypertension in alcohol-related cirrhosis</article-title>. <source>Clin Gastroenterol Hepatol</source>. <year>2023</year>;<volume>21</volume>(<issue>9</issue>):<fpage>2308</fpage>-<lpage>2317.e7</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.cgh.2022.11.033</pub-id><pub-id pub-id-type="pmid">36481475</pub-id>
</mixed-citation></ref></ref-list><notes notes-type="supplementary-material" id="note-ZLD250061-1"><supplementary-material id="note-ZLD250061-1-s" position="float" content-type="local-data"><label>Supplement 1.</label><caption><p>
eMethods
</p><p><bold>eTable.</bold>
<italic>ICD-9/10-CM</italic> diagnosis codes and procedure codes</p><p>
eReferences
</p></caption><media xlink:href="jamanetwopen-e2511619-s001.pdf"/></supplementary-material><supplementary-material position="float" content-type="local-data"><label>Supplement 2.</label><caption><p>
Data Sharing Statement
</p></caption><media xlink:href="jamanetwopen-e2511619-s002.pdf"/></supplementary-material></notes></back></article><!--requester-ID rluttrel-->